IGXT (Mkap $34 M) 2 US-Zulassungsanträge im 4Q + weiteres Produkt wartet auf FDA Zulassung (Seite 75)
eröffnet am 27.07.16 17:27:05 von
neuester Beitrag 21.03.24 14:04:18 von
neuester Beitrag 21.03.24 14:04:18 von
Beiträge: 1.197
ID: 1.235.830
ID: 1.235.830
Aufrufe heute: 0
Gesamt: 195.665
Gesamt: 195.665
Aktive User: 0
ISIN: US45822R1014 · WKN: A0RP0X
0,1465
EUR
0,00 %
0,0000 EUR
Letzter Kurs 11.05.24 Lang & Schwarz
Neuigkeiten
08.05.24 · globenewswire  |
08.04.24 · globenewswire |
05.04.24 · globenewswire |
21.03.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 1,1500 | +34,98 | |
| 1,0000 | +33,33 | |
| 6,5900 | +31,80 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,2500 | -19,23 | |
| 0,7300 | -19,34 | |
| 1,2700 | -19,62 | |
| 2,0150 | -21,29 | |
| 2.849,50 | -83,34 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 54.009.128 von allin123 am 04.01.17 16:13:12Here we go!!!
Eine 7-stellige Upfront Zahlung könnte realistisch sein.
Interressant auch das Rizaport bereits in 2017 für Umsatz sorgt (aus dem Redhill-Board):
HC Wainwright schreibt: Concordia Agreement Starts Off a Catalyst-rich 2017; Reiterate Buy Concordia agreement is a first step. On January 3, RedHill announced an agreement with Canadian specialty pharmaceuticals company Concordia International to co-promote Donnatal, a prescription drug used to treat mild to moderate irritable bowel syndrome (IBS), in certain undisclosed US territories. We believe this is an important first step in the management’s plan of building a commercial structure to directly market gastrointestinal (GI) and other primary care products in the US. According to management, the company intends to initially recruit up to 30 representatives and plans to begin promoting Donnatal in 2Q17. Based on Concordia’s 3Q16 financial reports, Donnatal achieved sales of $11.7M in 3Q16 despite significant market competition, and we expect the drug to maintain its market share in the medium term. While management has not disclosed the details of the co-promotion agreement, we assume that RedHill would operate in at least 30% of the overall Donnatal territories with a 50% revenue split, ramping up over 3 years. Based on these assumptions, we project RedHill to derive $702,000 of revenue from co-promotion of Donnatal in 2017, growing to $7.0M by 2019. We believe that, more important than the short-term revenues, this co-promotion agreement could provide RedHill with valuable commercial experience in the GI space before the company’s own GI-targeting products Bekinda, RHB-104 and RHB-105 reach the market over the next three years. We also expect management to expand the company’s GI product offerings through additional in-license or co-promotion agreements in the near future. 2017 could be a pivotal year. With several important commercial and clinical milestones coming up, we believe 2017 could be an important year for RedHill. Rizaport, the company’s oral film drug for the treatment migraines, is expected to launch in Spain in 2H17
, and US regulatory submission under the 505(b)2 pathway is expected later in the year. RedHill is also on-track to report the top-line results from the Phase 3 study of Bekinda for the treatment of acute gastritis and gastroenteritis (the GUARD study) around mid-2017. Other clinical results we expect to see from RedHill in 2017 include top-line results from the Phase 2 study of Bekinda for the treatment of IBS-D (mid-2017) and the interim DSMB safety and futility analysis of the Phase 3 study of RHB-104 for the treatment of Crohn’s disease (2Q17). We also expect RedHill to initiate a Phase 3 confirmatory study of RHB-105 for the treatment of H. pylori in 1H17 and expect this study to complete in 2018. Valuation. We are maintaining our Buy rating of RedHill and our 12- month price target of $33.00 per ADS based on the average of two valuation methods: 1) price-sales multiple using 7x 2025 sales estimate discounted at 14%; and 2) price-earnings multiple analysis applying a 15x multiple to our 2025 estimated earnings also discounted at 14%.
(RDHL) Mkap $61 M /Ein MUSS für jeden Biotech Investor | wallstreet-online.de - Vollständige Diskussion unter:
http://www.wallstreet-online.de/diskussion/1187335-411-420/r…
Nach wie vor eine lächerliche MK von $56M
Charttechnisch alle Ampeln auf grün!!!
Eine 7-stellige Upfront Zahlung könnte realistisch sein.
Interressant auch das Rizaport bereits in 2017 für Umsatz sorgt (aus dem Redhill-Board):
HC Wainwright schreibt: Concordia Agreement Starts Off a Catalyst-rich 2017; Reiterate Buy Concordia agreement is a first step. On January 3, RedHill announced an agreement with Canadian specialty pharmaceuticals company Concordia International to co-promote Donnatal, a prescription drug used to treat mild to moderate irritable bowel syndrome (IBS), in certain undisclosed US territories. We believe this is an important first step in the management’s plan of building a commercial structure to directly market gastrointestinal (GI) and other primary care products in the US. According to management, the company intends to initially recruit up to 30 representatives and plans to begin promoting Donnatal in 2Q17. Based on Concordia’s 3Q16 financial reports, Donnatal achieved sales of $11.7M in 3Q16 despite significant market competition, and we expect the drug to maintain its market share in the medium term. While management has not disclosed the details of the co-promotion agreement, we assume that RedHill would operate in at least 30% of the overall Donnatal territories with a 50% revenue split, ramping up over 3 years. Based on these assumptions, we project RedHill to derive $702,000 of revenue from co-promotion of Donnatal in 2017, growing to $7.0M by 2019. We believe that, more important than the short-term revenues, this co-promotion agreement could provide RedHill with valuable commercial experience in the GI space before the company’s own GI-targeting products Bekinda, RHB-104 and RHB-105 reach the market over the next three years. We also expect management to expand the company’s GI product offerings through additional in-license or co-promotion agreements in the near future. 2017 could be a pivotal year. With several important commercial and clinical milestones coming up, we believe 2017 could be an important year for RedHill. Rizaport, the company’s oral film drug for the treatment migraines, is expected to launch in Spain in 2H17
, and US regulatory submission under the 505(b)2 pathway is expected later in the year. RedHill is also on-track to report the top-line results from the Phase 3 study of Bekinda for the treatment of acute gastritis and gastroenteritis (the GUARD study) around mid-2017. Other clinical results we expect to see from RedHill in 2017 include top-line results from the Phase 2 study of Bekinda for the treatment of IBS-D (mid-2017) and the interim DSMB safety and futility analysis of the Phase 3 study of RHB-104 for the treatment of Crohn’s disease (2Q17). We also expect RedHill to initiate a Phase 3 confirmatory study of RHB-105 for the treatment of H. pylori in 1H17 and expect this study to complete in 2018. Valuation. We are maintaining our Buy rating of RedHill and our 12- month price target of $33.00 per ADS based on the average of two valuation methods: 1) price-sales multiple using 7x 2025 sales estimate discounted at 14%; and 2) price-earnings multiple analysis applying a 15x multiple to our 2025 estimated earnings also discounted at 14%.(RDHL) Mkap $61 M /Ein MUSS für jeden Biotech Investor | wallstreet-online.de - Vollständige Diskussion unter:
http://www.wallstreet-online.de/diskussion/1187335-411-420/r…
Nach wie vor eine lächerliche MK von $56M
Charttechnisch alle Ampeln auf grün!!!
Antwort auf Beitrag Nr.: 54.008.729 von allin123 am 04.01.17 15:46:23wunder mich immer nur, warum keine Zahlen onboard sind.
Ich schätze mal, das ist auch gewollt, damit man eine bessere Verhandlungsbasis ggü. weiteren potentiellen Partnern hat
Ich schätze mal, das ist auch gewollt, damit man eine bessere Verhandlungsbasis ggü. weiteren potentiellen Partnern hat
Antwort auf Beitrag Nr.: 54.008.675 von Popeye82 am 04.01.17 15:42:00alt...
aber das ist neu:
IntelGenx @IntelGenx 4 Min.vor 4 Minuten
Continued execution @IntelGenx announces Definitive Agreement with Chemo Group for a Generic CNS Tablet http://bit.ly/2hR0GJL
aber das ist neu:
IntelGenx @IntelGenx 4 Min.vor 4 Minuten
Continued execution @IntelGenx announces Definitive Agreement with Chemo Group for a Generic CNS Tablet http://bit.ly/2hR0GJL
Antwort auf Beitrag Nr.: 54.008.648 von Popeye82 am 04.01.17 15:39:20
- January 3, 2017 -- In this InvestorIntel interview, Dr. Horst G. Zerbe, President and CEO of IntelGenx Technologies Corp. (TSXV: IGX | OTCQX: IGXT) discusses the invention of their pharmaceutical oral film, VersaFilm™ and its drug delivery technology advantage. Dr. Zerbe says that their “objective is to improve the efficacy of a drug and its availability in the body.” Utilizing the VersaFilm™ technology, he comments upon IntelGenx's experimentation with the drug commonly used to treat asthma -- Montelukast.
He comments: “We discovered Montelukast as a great asset management opportunity. Montelukast has been approved for many years as a treatment for asthma. There is very, very impressive research that was recently published indicating that it could be a very effective Alzheimer’s treatment. That is very important for the patient because today there is no treatment available that can reverse the effects of the Alzheimer’s disease, but Montelukast has the potential to do that.” -- To access the full interview, click here
Disclaimer: IntelGenx Technologies Corp. is an advertorial member of InvestorIntel Corp. -
- January 3, 2017 -- In this InvestorIntel interview, Dr. Horst G. Zerbe, President and CEO of IntelGenx Technologies Corp. (TSXV: IGX | OTCQX: IGXT) discusses the invention of their pharmaceutical oral film, VersaFilm™ and its drug delivery technology advantage. Dr. Zerbe says that their “objective is to improve the efficacy of a drug and its availability in the body.” Utilizing the VersaFilm™ technology, he comments upon IntelGenx's experimentation with the drug commonly used to treat asthma -- Montelukast.
He comments: “We discovered Montelukast as a great asset management opportunity. Montelukast has been approved for many years as a treatment for asthma. There is very, very impressive research that was recently published indicating that it could be a very effective Alzheimer’s treatment. That is very important for the patient because today there is no treatment available that can reverse the effects of the Alzheimer’s disease, but Montelukast has the potential to do that.” -- To access the full interview, click here
Disclaimer: IntelGenx Technologies Corp. is an advertorial member of InvestorIntel Corp. -
Trading Spotlight
Antwort auf Beitrag Nr.: 53.999.081 von backonplastic am 03.01.17 14:56:06Guter Start 2017!
Wann die Zulassungen kommen liegt an FDA, wobei in 2017 die Anträge schneller seitens FDA bearbeitet werden sollen.
Wenn's so weitergeht sehen wir hoffentlich sehr bald den $1,00
Wann die Zulassungen kommen liegt an FDA, wobei in 2017 die Anträge schneller seitens FDA bearbeitet werden sollen.
Wenn's so weitergeht sehen wir hoffentlich sehr bald den $1,00
Antwort auf Beitrag Nr.: 53.999.081 von backonplastic am 03.01.17 14:56:06https://investorintel.com/sectors/biotech/biotech-tv/intelge…
Wünsche euch allen ein gesundes und fantastisches Jahr 2017!
Sagt mal, weiß jemand wann hier mit Meldungen von der FDA zu rechnen ist ? Da sollte doch im Q4 2016 bisschen was kommen wenn ich mich recht erinnere
Sagt mal, weiß jemand wann hier mit Meldungen von der FDA zu rechnen ist ? Da sollte doch im Q4 2016 bisschen was kommen wenn ich mich recht erinnere
Antwort auf Beitrag Nr.: 53.962.520 von allin123 am 27.12.16 23:34:49Guten Morgen Gemeinde.
Ich hoffe ihr habt die Feiertage gut überstanden
Ja irgendwie schon. Es handelt sich schließlich um eine sehr gute News.
Was mich ein wenig stört, ist dass immer Zahlen fehlen. Es wird von Milestones, Payments etc. gesprochen, diese werden allerdings NIE beziffert.
Mal abgesehen davon, dass wir zu unbekannt scheinen ist es doch traurig, das es hier nicht so langsam knallt. Cash ist genug vorhanden, die Story ist gut, Management ebenfalls.
Vielleicht fehlt auch Fantasie, da es sich nicht um einen klassischen Biostock handelt sondern Wirkstoffe vertrieben werden, die bereits existieren...
Wenn es daran liegen sollte, werden wir einen langsamen aber kontinuierlichen Wachstum erleben, wobei sich die Kurssteigerungen an den Zahlen orientieren werden.
Obligatorisch wird ein Nasdaq Listening ...ansonsten dümpeln wir glaub ich weiter ...
Habt einen schönen Tag
BOP
Ich hoffe ihr habt die Feiertage gut überstanden
Ja irgendwie schon. Es handelt sich schließlich um eine sehr gute News.
Was mich ein wenig stört, ist dass immer Zahlen fehlen. Es wird von Milestones, Payments etc. gesprochen, diese werden allerdings NIE beziffert.
Mal abgesehen davon, dass wir zu unbekannt scheinen ist es doch traurig, das es hier nicht so langsam knallt. Cash ist genug vorhanden, die Story ist gut, Management ebenfalls.
Vielleicht fehlt auch Fantasie, da es sich nicht um einen klassischen Biostock handelt sondern Wirkstoffe vertrieben werden, die bereits existieren...
Wenn es daran liegen sollte, werden wir einen langsamen aber kontinuierlichen Wachstum erleben, wobei sich die Kurssteigerungen an den Zahlen orientieren werden.
Obligatorisch wird ein Nasdaq Listening ...ansonsten dümpeln wir glaub ich weiter ...
Habt einen schönen Tag
BOP
Durchsuchen
